Premium
Expression of collagenase‐3 (matrix metalloproteinase‐13) in transitional‐cell carcinoma of the urinary bladder
Author(s) -
Boström Peter J.,
Ravanti Laura,
Reunanen Niina,
Aaltonen Vesa,
Söderström KarlOve,
Kähäri VeliMatti,
Laato Matti
Publication year - 2000
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/1097-0215(20001101)88:3<417::aid-ijc14>3.0.co;2-g
Subject(s) - collagenase , matrix metalloproteinase , transitional cell carcinoma , urinary bladder , interstitial collagenase , matrix metalloproteinase 9 , metalloproteinase , carcinoma , pathology , urinary system , transitional cell , medicine , cancer research , biology , urology , bladder cancer , cancer , enzyme , biochemistry
Expression of collagenase‐3 [matrix metalloproteinase‐13 (MMP‐13)] has been previously demonstrated in squamous‐cell carcinomas of both the head and neck and the vulva, cutaneous basal‐cell carcinomas, chondrosarcomas and melanomas. Using in situ hybridization, MMP‐13 mRNA expression was detected in 13 of 23 (52%) urinary bladder transitional‐cell carcinomas (TCCs). Expression was restricted to cells in the invading edges of tumors. No expression of MMP‐13 mRNA could be detected in normal urothelium. As detected by immunohistochemistry, MMP‐13 protein showed an expression pattern similar to that of MMP‐13 mRNA. Expression of MMP‐13 mRNA and protein was also detected in 2 bladder carcinoma cell lines (RT4 and T24). In these cell lines, TNF‐α potently induced MMP‐13 mRNA expression. Retinoids and a selective p38 inhibitor, SB203580, potently inhibited MMP‐13 mRNA expression. Our results demonstrate MMP‐13 expression in human urinary bladder carcinoma cells in vivo and in vitro and suggest that MMP‐13 may serve as a marker for transformation and invasion in urinary bladder TCCs. Int. J. Cancer 88:417–423, 2000. © 2000 Wiley‐Liss, Inc.